Literature DB >> 25120806

Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.

Shuigen Zhou1, Longxin Wang1, Guimei Li2, Zhengyu Zhang1, Jiandong Wang3.   

Abstract

Receptors tyrosine kinase of Eph superfamily plays an important role in human cancers. We previously found that EphB1 subtype is down-regulated in gastric cancer, colorectal cancer and ovary serous carcinoma. Fore the more, the decreased expression of EphB1 is related to invasion and metastasis in cancers. Although EphB1 has been revealed as an important receptor in cancers, our understanding of its roles in renal cell carcinoma (RCC) is limited. In the present study, using specific anit-EphB1 polyclonal antibody and immunohistochemistry, we evaluated EphB1 protein expression levels in RCC specimens surgically resected from 82 patients (including 62 conventional clear-cell RCC, 10 papillary, and 10 chromophobic RCC cases). We found EphB1 protein is positively expressed in the epithelium of renal tubules. Decreased expression of EphB1 was found in all RCC carcinomas compared with expression in the normal epithelium of renal tubules. EphB1 protein moderately expressed in chromophobic RCC, weakly expressed in clear-cell RCC and negatively expressed in papillary RCC. Our results indicate that EphB1 may be involved in carcinogenesis of RCC, the molecular mechanisms of down-regulation of EphB1 including genetic and epigenetic alterations and the dedicated roles of EphB1 in occurrence and progress of RCC need to be explicated in next step.

Entities:  

Keywords:  EphB1; down-regulation; renal cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25120806      PMCID: PMC4129041     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

1.  Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival.

Authors:  Lei Teng; Mitsutoshi Nakada; Natsuki Furuyama; Hemragul Sabit; Takuya Furuta; Yutaka Hayashi; Takahisa Takino; Yu Dong; Hiroshi Sato; Yoshimichi Sai; Ken-Ichi Miyamoto; Michael E Berens; Shi-Guang Zhao; Jun-Ichiro Hamada
Journal:  Neuro Oncol       Date:  2013-10-11       Impact factor: 12.300

2.  Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.

Authors:  E R Woodward; S C Clifford; D Astuti; N A Affara; E R Maher
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

3.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

Authors:  Peter Schraml; Kirsten Struckmann; Florian Hatz; Stefan Sonnet; Charlotte Kully; Thomas Gasser; Guido Sauter; Michael J Mihatsch; Holger Moch
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

4.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

5.  Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).

Authors:  Rashmi Bhat Singh; Pratibha S Amare Kadam
Journal:  Urol Oncol       Date:  2011-10-01       Impact factor: 3.498

6.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.

Authors:  H Brauch; G Weirich; J Brieger; D Glavac; H Rödl; M Eichinger; M Feurer; E Weidt; C Puranakanitstha; C Neuhaus; S Pomer; W Brenner; P Schirmacher; S Störkel; M Rotter; A Masera; N Gugeler; H J Decker
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

7.  Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Authors:  Haifa Shen; Cristian Rodriguez-Aguayo; Rong Xu; Vianey Gonzalez-Villasana; Junhua Mai; Yi Huang; Guodong Zhang; Xiaojing Guo; Litao Bai; Guoting Qin; Xiaoyong Deng; Qingpo Li; Donald R Erm; Burcu Aslan; Xuewu Liu; Jason Sakamoto; Arturo Chavez-Reyes; Hee-Dong Han; Anil K Sood; Mauro Ferrari; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

8.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.

Authors:  N de Paulsen; A Brychzy; M C Fournier; R D Klausner; J R Gnarra; A Pause; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

9.  Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients.

Authors:  Kazuya Nagano; So-Ichiro Kanasaki; Takuya Yamashita; Yuka Maeda; Masaki Inoue; Kazuma Higashisaka; Yasuo Yoshioka; Yasuhiro Abe; Yohei Mukai; Haruhiko Kamada; Yasuo Tsutsumi; Shin-Ichi Tsunoda
Journal:  Cancer Med       Date:  2013-11-07       Impact factor: 4.452

Review 10.  Eph receptors in breast cancer: roles in tumor promotion and tumor suppression.

Authors:  David Vaught; Dana M Brantley-Sieders; Jin Chen
Journal:  Breast Cancer Res       Date:  2008-12-22       Impact factor: 6.466

View more
  2 in total

1.  Loss-of-function uORF mutations in human malignancies.

Authors:  Julia Schulz; Nancy Mah; Martin Neuenschwander; Tabea Kischka; Richard Ratei; Peter M Schlag; Esmeralda Castaños-Vélez; Iduna Fichtner; Per-Ulf Tunn; Carsten Denkert; Oliver Klaas; Wolfgang E Berdel; Jens P von Kries; Wojciech Makalowski; Miguel A Andrade-Navarro; Achim Leutz; Klaus Wethmar
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

Review 2.  Paradoxes of the EphB1 receptor in malignant brain tumors.

Authors:  Wenqiang Wei; Hongju Wang; Shaoping Ji
Journal:  Cancer Cell Int       Date:  2017-02-08       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.